Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Troy E. Wilson
|
| gptkbp:clinicalTrialPhase |
KO-539 for acute myeloid leukemia
tipifarnib for HRAS mutant HNSCC |
| gptkbp:focus |
oncology
cancer therapeutics |
| gptkbp:foundedYear |
2014
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kura Oncology
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:numberOfEmployees |
~100 (as of 2023)
|
| gptkbp:products |
gptkb:tipifarnib
KO-2806 KO-539 |
| gptkbp:specializesIn |
targeted cancer therapies
precision medicines |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:KURA
|
| gptkbp:website |
https://kuraoncology.com/
|
| gptkbp:bfsParent |
gptkb:tipifarnib
|
| gptkbp:bfsLayer |
7
|